- Catalyst and Auxiliary
- Agrochemicals
- Organic Chemicals
- Adhesive and Sealant
- Basic Inorganic Chemicals
- Pharmaceutical
- Plant Extract
- Food Additives
- Others
Sunmore Healthcare Co., LTD.
Country: 
China (Mainland)
China (Mainland)
Business Type: Trading Company
Ms.sir
Tel: 18273476892
Fax:
City: Changsha City
Street: 2203, Xinglong International Plaza
MaxCard:
Azithromycin in stock Supply 121470-24-4 C38H72N2O12 CAS NO.83905-01-5
- Min.Order: 0 Metric Ton
- Payment Terms:
- Product Details
Keywords
- Azithromycin in stock
- Supply 121470-24-4
- Azithromycin manufacturer
Quick Details
- ProName: Azithromycin in stock Supply 121470-24...
- CasNo: 83905-01-5
- Molecular Formula: C38H72N2O12
- Appearance: White or off white crystalline powder
- Application: Semi-synthetic macrolide antibiotic
- DeliveryTime: Within 5-7 days
- PackAge: 25kg/drum
- Port: china
- ProductionCapacity: Metric Ton/Day
- Purity: Above 99%
- Storage: Store in a cool, dry place away from s...
- Transportation: by sea, air or express
- LimitNum: 0 Metric Ton
- Valid Period: 7 days
Superiority
Azithromycin in stock Supply 121470-24-4 C38H72N2O12
[Precautions]
(1) It is prohibited for people who are allergic to this product, erythromycin or any other macrolide drugs.
(2) The advantages and disadvantages of pregnant women should be fully weighed; The application to lactating women should be carefully considered; The efficacy and safety of the treatment of otitis media, community-acquired pneumonia, and pharyngitis or tonsillitis in children less than 6 months of age have not been established.
(3) There is no need for dose adjustment in patients with mild renal insufficiency (creatinine clearance rate >40ml/min), but it should be used with caution in patients with more severe renal insufficiency.
(4) Because the hepatobiliary system is the main way for the excretion of this product, it should be used with caution in patients with liver dysfunction and should not be used in patients with severe liver disease. Liver function was followed up regularly during medication.
(5) Eating can affect the absorption of azithromycin, so it should be taken orally 1h before or 2h after meals.
(6) If allergic reactions (such as angioneurotic edema, skin reaction, StevensJohnson syndrome, toxic epidermal necrosis, etc.) occur during medication, the drug should be stopped immediately and appropriate measures should be taken. Pseudomemmembranous colitis should be considered in patients with diarrhea, and if the diagnosis is established, appropriate treatment measures should be taken, including maintaining water and electrolyte balance, and protein supplementation.
(7) in the treatment of pelvic inflammatory disease if suspected combined with anaerobe infection, should be combined with anti-anaerobe drugs.
Details
[Clinical evaluation]
The treatment of acute lower respiratory tract infection was compared between azithromycin and cefclo. The azithromycin group was 191 cases, once a day, for 5 consecutive days, 0.5g for the first time, and 0.25g for each time thereafter. 81 cases in cefclone group were given 0.5 g each time, 3 times a day for 10 consecutive days. The clinical cure rate and improvement rate were 96% and 94% respectively in the two groups, and the bacteriological clearance rate was 88%.
The total effective rate was 93.6%, the bacterial clearance rate was 91.4%, and the incidence of adverse reactions was 5.4%.
This product by Neisseria gonorrhoeae, chlamydia trachomatis, mycoplasma caused by the urinary genital system infection has an excellent effect.
Shanghai Cutaneous Venereal Disease Prevention and Control Center used this product in the treatment of non-Neisseria gonorrhoeae urethritis and gonorrhoea patients, in which 30 cases of chlamydia infection, 19 cases of mycoplasma infection, 28 cases of Neisseria gonorrhoeae infection, oral administration, single dose of 1 g, the cure rate was 100%, 85%, 96.5%, the total effective rate was 100%.
Previous studies have linked azithromycin to an increased risk of cardiovascular death in high-risk individuals. But there has been a lack of research in real world populations. To that end, a large, real-world population study. This is a national historical cohort study of 18- to 64-year-olds in Denmark, associated prescription registry databases, causes of death, and general patient outcomes between 1997 and 2010. A total of 1.1 million courses of azithromycin were evaluated compared with the control group who did not receive antibiotics (1:1 propensity score matching). In addition, 7.36 million patients using penicillin V were compared with the control group (also matching according to propensity score) to see cardiovascular cause deaths.
The results showed a significant increased risk of cardiovascular death between azithromycin and no antibiotic (RR: 2.85, 95CI: 1.13-7.24).
There were 17 patients died in the azithromycin group and 146 patients died in the penicillin V group (RR: 0.93, 95%CI: 0.56-1.55). Azithromycin did not increase the risk of cardiovascular death in younger and older patients.